Dermorphin

What it is

dermorphin is a naturally occurring heptapeptide (Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH₂) originally isolated from the skin of South American Phyllomedusa frogs. It is the founding member of the D-amino acid-containing opioid peptide family from amphibian skin, which also includes the delta-selective deltorphins. The critical structural feature of dermorphin is the D-alanine residue at position 2, which confers resistance to enzymatic degradation (metabolic stability) and is essential for high-affinity mu (μ)-opioid receptor binding (PMID 30538538, PMID 10462042). Dermorphin is a highly selective and potent mu-opioid receptor (MOR) agonist. Its analgesic potency has been reported as substantially greater than morphine in multiple experimental models and in clinical intrathecal application. The N-terminal tetrapeptide sequence Tyr-D-Ala-Phe-Gly represents the minimal pharmacophore required for opioid activity at MOR; the C-terminal residues (Tyr-Pro-Ser-NH₂) modulate receptor selectivity and pharmacokinetic properties. The N-terminus tyrosine residue adopts a specific active conformation critical for opioid receptor engagement. At the cellular level, MOR activation by dermorphin follows the canonical opioid receptor signaling cascade: Gαi/o coupling inhibits adenylyl cyclase (reducing cAMP), activates inwardly rectifying K⁺ channels (GIRK), and inhibits voltage-gated Ca²⁺ channels — collectively reducing neuronal excitability and synaptic transmission in pain circuits. A distinctive feature of some dermorphin analogs (d-Arg² substituted tetrapeptides) is the stimulation of dynorphin release at spinal cord level through MOR, which secondarily engages kappa-opioid receptors — a mechanism proposed to reduce tolerance development compared to morphine. Novel dermorphin analogs (D2, D3, D4) with cyclic structures or modified sequences retain potent MOR agonism and show activity via intranasal and intraperitoneal routes in rodents, demonstrating peripheral bioavailability and central access. Dermorphin has also been used as a targeting ligand in immunotoxin constructs (dermorphin-saporin) for selective ablation of MOR-expressing neurons in pain research.

Class: Natural heptapeptide opioid / selective mu (μ)-opioid receptor agonist — isolated from Phyllomedusa frog skin

What it's studied for

• Analgesia — postoperative and acute pain (intrathecal) Human RCT
  • Review documenting a 1985 RCT (cited within): intrathecal dermorphin vs. morphine for postoperative pain — dermorphin produced superior analgesia compared to intrathecal morphine. Authors describe compound as 'largely abandoned clinically' despite positive results and argue for renewed investigation. Intrathecal route, PMID 30538538 Hesselink JMK et al. J Pain Res. 2018.
• Analgesia via peripheral and intranasal routes — novel analog development Animal studies only
  • Synthetic dermorphin analogs D2, D3, D4: intranasal D2 at 1.0 µg/kg produced maximal long-lasting analgesia in rats/mice; 0.5 µg/kg gave 40% analgesia. IP D3/D4 at 5.0 mg/kg yielded >50% pain relief. Cyclopeptide versions (D3, D4) incorporating 2,5-diketopiperazine scaffold show promise for oral administration. Behavio PMID 40943359 Deigin V et al. Int J Mol Sci. 2025.
  • Review of dermorphin tetrapeptide analogs with d-Arg² substitutions: antinociceptive potency exceeds morphine across multiple administration routes while maintaining μ-selectivity. A key finding: d-Arg²-dermorphin analogs stimulate dynorphin release via MOR, secondarily activating κ-opioid receptors — proposed mechanis PMID 21126548 Mizoguchi H et al. Peptides. 2011.
• Mu-opioid receptor pharmacology — structure-activity relationships In vitro only
  • SAR library (18 analogs via Suzuki-Miyaura cross-coupling on Phe³): subnanomolar MOR binding affinities with modulated μ/δ selectivity achievable. Establishes dermorphin scaffold as a template for tunable opioid receptor selectivity. PMID 29853330 Willemse T et al. Bioorg Med Chem Lett. 2018.
  • Organometallic blocking group scan identified two distinct dermorphin binding modes at MOR: conventional N-terminal and unprecedented C-terminal mode. Both showed high affinity and agonist activity in vitro; C-terminal mode produced dose-dependent antinociception in vivo. Suggests natural dermorphin may access the rece PMID 27553294 Strack M et al. Chemistry. 2016.
• Targeted neuronal ablation — mu-opioid receptor-expressing pain neurons Animal studies only
  • Dermorphin-saporin immunotoxin microinjected into rat rostral ventromedial medulla selectively ablated MOR-expressing descending facilitatory pain neurons. 3-month observation: minimal acute cardiovascular effects, no sustained physiological dysfunction, mild microglial activation at day 7 without significant neuroinfl PMID 19559047 Cao F et al. Neurotoxicology. 2009.
• Brain-targeted peptide drug delivery — antibody vector approach Animal studies only
  • Dermorphin conjugated to anti-transferrin receptor antibody (OX26) via cleavable disulfide linker: ICV injection confirmed biological activity (analgesia, naloxone-reversible). Disulfide linker cleaved in rat plasma and brain. Demonstrates feasibility of antibody-mediated brain-targeted delivery of dermorphin with rele PMID 7599264 Bickel U et al. Bioconjug Chem. 1995.

Community-reported dosing

Tier key: Research = PMID-cited study · [C] = scraped community source · [S] = model-synthesized from aggregate community reports (softer evidence). How we source.

Safety signals

• Dermorphin is a potent mu-opioid agonist with analgesic potency reportedly exceeding morphine. Class-effect risks include respiratory depression, sedation, nausea/vomiting, and opioid dependence liability. PMID 30538538
• Novel dermorphin analog D2 at 1.0 µg/kg intranasal produced complete stupor in rodents, indicating extremely high potency and narrow therapeutic window. At 0.5 µg/kg, 40% analgesia without complete stupor was observed. PMID 40943359
• Dermorphin-saporin ICV injection: mild microglial activation at day 7 post-injection without significant astrocyte upregulation or proinflammatory cytokines, and no sustained physiological dysfunction over 3 months. PMID 19559047

Contraindications

• Respiratory compromise — mu-opioid agonists are contraindicated in patients with significant respiratory impairment given respiratory depression risk inherent to MOR activation. PMID 30538538
• No formal contraindications established in reviewed literature for exogenous dermorphin in humans beyond general mu-opioid contraindications. No approved therapeutic product exists; clinical use outside specialized intrathecal pain settings is not supported by evidence. PMID 30538538